Editas Medicine, Inc. cash flow to debt ratio of -215.42% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Editas Medicine, Inc.'s free cash flow has increased -24.31% from $-219.11M last year to $-165.85M, signaling increasing performance

Editas Medicine, Inc.'s debt to equity ratio is 0.15, which means that the company's assets are healthy financed, signaling financial stability.

Editas Medicine, Inc.'s debt has decreased relative to shareholder equity from 0.26 last year to 0.15 today, signaling strengthened financials

Editas Medicine, Inc. has a net cash position, so leverage is healthy.

Editas Medicine, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Editas Medicine, Inc.'s profit margin has increased (-78.56%) in the last year from -733.72% to -157.32%, signaling increasing performance

Editas Medicine, Inc.'s short-term assets of $163.90M exceed its short-term liabilities of $46.25M

Editas Medicine, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Editas Medicine, Inc.'s return on equity of -196.63%, is lower than 15.00%, indicating bad performance

Editas Medicine, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Editas Medicine, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Editas Medicine, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Editas Medicine, Inc. has negative free cash flow, indicating cash burn

Editas Medicine, Inc.'s yearly earnings has increased -32.49% since last year from $-237.09M to $-160.06M, signaling increasing performance

Editas Medicine, Inc.'s yearly revenue has decreased 100.00% since last year from $32.31M to $0.00, signaling decreasing performance

ROIC -46.81% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Editas Medicine, Inc.'s 3-year revenue CAGR of 27.15% is positive, indicating growing revenue over the past 3 years

Editas Medicine, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Editas Medicine, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Editas Medicine, Inc. has insufficient data to evaluate this check.

Editas Medicine, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Editas Medicine, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Editas Medicine, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Editas Medicine, Inc. has insufficient data to evaluate this check.

Editas Medicine, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Editas Medicine, Inc. has a price-to-book ratio of 3.18x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Editas Medicine, Inc. has a price-to-sales ratio of 7.13x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue